Latest Research Updates on SWAG Network Hepato-Pancreato-Biliary (HPB) Cancer
This update includes information on SWAG Network's HPB cancer studies, national recruitment to upper GI cancer studies, and regional recruitment data. It also lists various ongoing HPB cancer research studies with details on sample sizes, recruitment sites, and study timelines.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
SWAG Network Hepato- pancreato-biliary (HPB) cancer Clinical Advisory Group Research Update - Claire Matthews & Sharath Gangadhara 27/01/2023
National Recruitment to Upper GI Cancer Studies Apr 2022 - Jan 2023 Apr 2021 - Mar 2022 Data cut 24/01/2023 Source: ODP All Portfolio
National vs Regional Recruitment to Upper GI Cancer Studies National Recruitment West of England Recruitment Data cut 24/01/2023 Source: ODP All Portfolio
SWAG region Open HPB Cancer Studies Sample Size Eng Eng Recruits CPMS ID Short Name Sites Opening Closure VAPOR STUDY 53691 Yeovil 15/12/2022 31/07/2024 963 5 PRIMER-1 51779 Sal 25/08/2022 01/06/2024 54 0 SELINA 49848 NBT, Yeovil, Sal 01/04/2022 30/11/2023 250 29 Pearl 49759 UHBW, GHFT 23/02/2022 31/07/2023 3000 536 GRECO-2 49307 UHBW 03/02/2022 30/11/2023 6 1 PORCUPINE2 STUDY 48280 UHBW 01/12/2021 31/05/2023 40 15 NIS793 in combination with gemcitabine and nab-paclitaxel for mPDAC 47681 UHBW, Sal 30/05/2022 31/07/2023 10 8 OSPREY 46784 Sal 12/05/2021 04/04/2026 40 0 Checkpoint inhibitor-induced liver injury study 45983 Yeovil 28/09/2020 01/09/2023 160 145 The PROOF Trial 45260 Sal 30/10/2020 01/01/2025 11 1 STARPAC2 44007 UHBW 22/04/2022 31/10/2023 159 3 LEAP-012 43212 Sal 25/03/2021 06/12/2024 15 0 CRUK HUNTER Accelerator delivering immunotherapy for liver cancer 42961 Sal 11/12/2019 30/11/2023 1450 553 UK-EDI: UK Early Detection Initiative for Pancreatic Cancer 42837 Yeovil, NBT, Sal 18/12/2020 08/06/2023 2200 169 Questions to Predict Disease Risk (RISQ) 42781 Yeovil 06/02/2020 31/05/2029 4000 452 TACE-3 39879 UHBW 08/08/2019 31/12/2024 380 57 PrecisionPanc (Lead: Scotland) 37518 UHBW 28/11/2017 31/12/2024 500 268 PRIMUS 001 (Lead: Scotland) 36511 BHOC, NBT 28/11/2017 31/12/2024 250 174 SALIVA TO PREDICT DISEASE RISK (version 1) 33908 Sal 06/04/2017 01/03/2023 5000 2759 PHITT 33836 BRHC 25/08/2017 31/12/2023 106 102 NIHR BioResource - Rare Diseases 15941 UHBW, RUH, NBT, Sal 13/09/2012 30/11/2024 22000 16210
SWAG region In Setup HPB Cancer Studies CPM S No. Short Name Sites Planned Opening Planned Closure Sample Size Eng Sample Size UK EvIDHence -Longitudinal retrospective CCA chart review study 53394 UHBW, Sal 31/01/2023 15/04/2023 - 32 43749 PRIMUS 004 (metastatic pancreatic cancer) UHBW 31/05/2022 01/08/2026 30 80 50304 MAP-1 v2 (Markers in Acute Pancreatitis) Yeovil 01/01/2023 31/12/2023 250 300 National In Setup HPB Cancer Studies (open to new sites) CPMS Study ID Short Name Title Planned Opening Planned Closure Sample Size Eng 38580 BBC Phase II study of neoadjuvant cisplatin and gemcitabine chemotherapy versus upfront surgery in patients with resectable proximal biliary tract cancer: 01/03/2019 15/06/2019 72
Research Delivery Manager claire.matthews@nihr.ac.uk Research Portfolio Facilitator rebecca.pienaar@nihr.ac.uk Sub Specialty Lead sharath.gangadhara@nhs.net
